

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During the scoping workshop, consultees noted that there is a degree of underdiagnosis of obstructive HCM. This means that some people with HCM are treated for cardiac symptoms, without specifically being treated for obstructive HCM. If they are found to have an ejection fraction above that considered for treatment for heart failure they may be discharged from specialist cardiac care.

Because mavacamten will be specifically indicated for people with obstructive HCM, consultees considered that this could have an additional benefit via increased recognition of symptoms and testing meaning people would receive appropriate treatment at an earlier stage of disease. It was noted that this benefit may not be captured in the appraisal.

It was suggested by consultees that this may be an equalities issue, that some people do not receive a diagnosis and therefore current standard of care.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The NICE technical team considers this to be an equalities issue outside the remit of the committee based on current available information. However, it is recommended that the committee further explores whether underdiagnosis is likely to have greater impact on specific groups of people with protected

characteristic under the Equality Act 2010.

The company and experts were informed that uncaptured benefit may be considered by the committee at the time of the appraisal. Any information about this can be included within their submissions to NICE.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

**Approved by Associate Director (name):** Jasdeep Hayre

**Date:** 26 January 2022